Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.

ABSTRACT:

SUBMITTER: Bannerji R 

PROVIDER: S-EPMC10681157 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature